首页> 外文期刊>Urology >Safety and efficacy of mini-margin nephron-sparing surgery for renal cell carcinoma 4-cm or less.
【24h】

Safety and efficacy of mini-margin nephron-sparing surgery for renal cell carcinoma 4-cm or less.

机译:小剂量肾保留肾手术治疗4厘米或以下的肾细胞癌的安全性和有效性。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: To explore whether mini-margin nephron-sparing surgery (NSS) is clinically safe and effective for renal cell carcinoma (RCC) of 4 cm or less with a normal contralateral kidney. METHODS: A total of 115 patients with sporadic, pathologically confirmed RCC of 4 cm or less (Stage T1a), with a normal contralateral kidney, were treated by NSS using a mini-margin of less than 5 mm from 1998 to 2006. The surgical margin status was evaluated by both frozen and permanent paraffin section studies. The patients were followed up, and the data were analyzed. RESULTS: The mean and median tumor diameter was 3.3 and 3.5 cm (range 1.0 to 4.0). None of the patients had positive surgical margins detected at either frozen section or final paraffin section analysis. The mean margin width was 2.2 mm (median 2.0, range 0 to 6). Of the 115 patients, 114 had margins of 5 mm or less (99.1%), 97 (84.3%) had margins of 3 mm or less, and 26 had margins of 0 mm (22.6%). At a mean follow-up of 65 months (median 66, range 9 to 105), all patients were alive. No distant metastasis was detected. Local recurrence was detected in 1 patient (0.9%) at a different site in the kidney. No major surgical complications, such as hemorrhage or urinary leakage/urinoma requiring reoperation, occurred. Considering only the 97 patients with follow-up of more than 3 years in the analysis, the mean and median follow-up time was 73 and 69 months (range 37 to 105), respectively. All 97 patients were alive with no evidence of disease at the last visit. CONCLUSIONS: The results of our study have shown that mini-margin NSS is a safe and effective approach for treating early localized RCC of 4 cm or less.
机译:目的:探讨对于正常对侧肾脏而言,微距保肾术(NSS)对于4 cm或更小的肾细胞癌(RCC)在临床上是否安全有效。方法:1998年至2006年,共115例经病理证实的散发性RCC为4厘米或更小(T1a期),对侧肾脏正常的患者接受了NSS治疗,其最小切缘小于5毫米。边缘状态通过冷冻和永久石蜡切片研究进行评估。对患者进行随访,并分析数据。结果:平均和中位肿瘤直径分别为3.3和3.5 cm(范围为1.0至4.0)。在冷冻切片或最终石蜡切片分析中,没有患者的手术切缘阳性。平均边距宽度为2.2毫米(中位数为2.0,范围为0至6)。在115例患者中,有114例的切缘为5毫米或更小(99.1%),有97例(84.3%)的切缘为3毫米或更小,有26例的切缘为0毫米(22.6%)。平均随访65个月(中位数66,范围9至105),所有患者均存活。未检测到远处转移。 1名患者(0.9%)在肾脏的其他部位检测到局部复发。没有发生需要手术的大手术并发症,例如出血或尿漏/尿液瘤。在分析中仅考虑97名随访超过3年的患者,平均随访时间和中位随访时间分别为73和69个月(范围37至105)。在最后一次访视时,所有97名患者均活着,没有疾病迹象。结论:我们的研究结果表明,微距NSS是治疗4 cm或更小的早期局部RCC的安全有效方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号